Shionogi Extends Research Partnership with MorphoSys
Complete the form below to unlock access to ALL audio articles.
MorphoSys AG has announced that Shionogi & Co., Ltd., Osaka, Japan, has elected to extend its current license agreement covering the use of MorphoSys's HuCAL technology in drug discovery, for three additional years.
Under the terms of the agreement, Shionogi will continue to have the right to use MorphoSys's proprietary antibody library HuCAL GOLD for research purposes at one of its research sites. MorphoSys will receive annual user fees from Shionogi for access to the HuCAL technology. Further financial details were not disclosed.
"We are very pleased with Shionogi's decision to continue using our HuCAL GOLD technology as a research tool. Today's news underscores our ongoing ability to pursue a broad range of R&D-based alliances with leading pharmaceutical companies worldwide," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys.
MorphoSys and Shionogi signed a three-year license agreement on the use of MorphoSys's HuCAL technology in September 2005.
Under the terms of the agreement, MorphoSys granted Shionogi access to its HuCAL GOLD antibody library for research applications in Shionogi's drug discovery programs.
